Skip to content

Gaius Therapeutics

Cell therapies for autoimmune disease

Raised to date

$60K

of $250K offered across 1 Form D filing

Still open
$190K
Investors
2
Last filed
May 14, 2026

About

Gaius Therapeutics is a San Diego biotech founded in 2026 that develops cell therapies for autoimmune disease. CB Insights describes its work as engineering CAR-Treg cells for autoimmune conditions. A co-founder describes a machine-learning-guided discovery platform for genetic switches used to design in vivo cell therapies.

Machine-learning-guided genetic switch discovery to design in vivo cell therapies precise enough for autoimmune disease.

Funding

  • Security to be acquiredFiled May 14, 2026Form D
    $60K/ $250K

Product

CAR-Treg cell therapies

Cell therapy

Early-stage cell therapies for autoimmune disease, designed with a machine-learning-guided genetic switch discovery platform.

  • CAR-Treg cell engineering
  • Machine-learning-guided genetic switch discovery
  • In vivo cell therapy design

Built for

Patients with autoimmune disease

People on file